Compare OCSL & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCSL | SPTX |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2007 | 2026 |
| Metric | OCSL | SPTX |
|---|---|---|
| Price | $13.11 | $23.87 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $12.63 | N/A |
| AVG Volume (30 Days) | ★ 561.2K | 104.0K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | ★ 12.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.31 | N/A |
| P/E Ratio | $65.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.63 | $17.59 |
| 52 Week High | $14.31 | $26.32 |
| Indicator | OCSL | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 65.39 | 61.29 |
| Support Level | $12.31 | $18.72 |
| Resistance Level | $13.86 | N/A |
| Average True Range (ATR) | 0.29 | 1.45 |
| MACD | 0.06 | 0.10 |
| Stochastic Oscillator | 92.04 | 62.75 |
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies and manages the business on a consolidated basis.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.